Key Takeaway: Altimmune, Inc. announced its participation in two upcoming investor conferences, where its management team will be available for one-on-one meetings. The sessions will be webcast, allowing broader access for interested investors. Altimmune focuses on developing peptide-based therapeutics for liver and cardiometabolic diseases, with its lead candidate being pemvidutide.
Price reaction · baseline $3.76 (2025-11-04 close) · hit pre-market · 2 other ALT headline(s) in the window, move may be shared
day 0 close
-0.3%
Market Sentiment Analysis
POSITIVE FACTORS
Altimmune is participating in two upcoming investor conferences.
Management will be available for one-on-one meetings.
The sessions will be webcast, increasing accessibility.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+22%
120-day peak, hindsight
Typical move
10.2%
average across 8 past catalysts
Cash runway
~64 mo
Minimal dilution risk
Lead asset
ALT-801
Phase 2 · Obesity/Overweight
Full Press Release Details
GAITHERSBURG, Md., Nov. 05, 2025 (GLOBE NEWSWIRE) --Altimmune, Inc.(Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the Company’s management team will participate and be available for one-on-one meetings at the following investor conferences:
The sessions will be webcast and can be accessed by visiting theEventssection of the Altimmune website.
About Altimmune
Altimmune is a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases. The Company’s lead product candidate is pemvidutide, a glucagon/GLP-1 dual receptor agonist for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). For more information, please visitwww.altimmune.com.
Follow @Altimmune, Inc. onLinkedInFollow @AltimmuneInc onX